FDA approves Tercica's growth disorder drug

The FDA has approved Tercica's Somatuline Autogel, an injectable treatment for adult patients with acromegaly. Acromegaly is a rare disorder caused by too much growth hormone, resulting in enlarged body tissues of the face, jaw, hands, feet and skull. The approval is good news for Ipsen; last year the company granted Tercica development and commercialization rights to the drug, and Ipsen will gain a $41 million milestone payment from Tercica.

- see this press release for more

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.